Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 896.82 +2.83 (+0.32%) Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 507,468 Open 913.97 Bid (Size) 841.00 (1) Ask (Size) 902.45 (1) Prev. Close 893.99 Today's Range 891.46 - 920.73 52wk Range 684.80 - 998.33 Shares Outstanding 91,779,465 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) April 18, 2024 From Kirby McInerney LLP Via GlobeNewswire Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry April 18, 2024 Via Benzinga Performance YTD -0.90% -0.90% 1 Month -7.25% -7.25% 3 Month -3.92% -3.92% 6 Month +10.93% +10.93% 1 Year +12.37% +12.37% More News Read More REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm April 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today April 17, 2024 Via Benzinga Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views April 12, 2024 Via Benzinga Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking April 11, 2024 Via Benzinga Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends March 28, 2024 Via Benzinga Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick April 17, 2024 Via Benzinga The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors April 17, 2024 From Law Offices of Frank R. Cruz Via Business Wire Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review April 12, 2024 Via Investor's Business Daily Topics Economy Exposures Interest Rates Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals March 26, 2024 Via Benzinga Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug April 11, 2024 Via Benzinga Topics Fraud Exposures Legal INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm April 11, 2024 From Schall Law Via GlobeNewswire Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity? April 11, 2024 Via Investor's Business Daily Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma April 07, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Should You Sell This Stock Following a Regulatory Roadblock? April 05, 2024 Via The Motley Fool 5 Healthcare Stocks to Buy for 2024 April 02, 2024 Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 April 01, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today April 01, 2024 Via Benzinga Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback March 28, 2024 Via Investor's Business Daily Exposures Product Safety Stock-Split Watch: Are These 2 Top Growth Stocks Next? March 28, 2024 Via The Motley Fool 3 Biotech Stocks to Buy for the Next Bull Run: March 2024 March 26, 2024 Via InvestorPlace FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns March 25, 2024 Via Benzinga Exposures Product Safety Regeneron Provides Update on Biologics License Application for Odronextamab March 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs March 22, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.